Small fibre integrity and axonal pathology in the rat model of experimental autoimmune neuritis.
autoimmune neuropathies
experimental autoimmune neuritis
pain
small fibres
Journal
Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125
Informations de publication
Date de publication:
2024
2024
Historique:
received:
07
02
2023
revised:
16
11
2023
accepted:
29
02
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
epublish
Résumé
Experimental autoimmune neuritis is a common animal model for acute human immune-mediated polyneuropathies. Although already established in 1955, a number of pathophysiological mechanisms remain unknown. In this study, we extensively characterize experimental autoimmune neuritis progression in Lewis rats, including new insights into the integrity of small nerve fibres, neuropathic pain and macrophage activation. Acute experimental autoimmune neuritis was induced with P2
Identifiants
pubmed: 38482371
doi: 10.1093/braincomms/fcae059
pii: fcae059
pmc: PMC10935649
doi:
Types de publication
Journal Article
Langues
eng
Pagination
fcae059Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.
Déclaration de conflit d'intérêts
R.K. received research funding from The LFB Group, France and the Ruhr-University Bochum, not related to this work. T.G. received travel reimbursement from Sanofi Genzyme and Biogen Idec, none related to this manuscript. J.M. received travel grants from Biogen idec, Novartis AG, Teva and Eisai GmbH; his research was funded by the Klaus Tschira Foundation and the Ruhr-University, Bochum (FoRUM programme), Hertie Foundation; Biogen idec and Deutsche Forschungsgemeinschaft, none related to this work. R.G. serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd, Biogen Idec, Bayer Schering Pharma and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd, Bayer Schering Pharma and Novartis; serves as an editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd, Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono and Novartis, none related to this manuscript. K.P. received travel funding and speaker honoraria from Biogen, Novartis, CSL Behring and Bayer Schering Pharma and funding from the Ruhr-University, Bochum (FORUM programme), none related to this work. The remaining authors report no competing interests.